Immunic AG

Quick facts

Phase 3 pipeline

• IMU-838 tablets · Immunology
  IMU-838 is a selective immunomodulator that inhibits dihydroorotate dehydrogenase (DHODH) to reduce proliferation of activated lymphocytes while preserving regulatory T cells.
• Placebo matching IMU-838 tablets · Immunology
  IMU-838 is a selective immunomodulator that inhibits intracellular signaling pathways to reduce pathogenic immune responses.

Phase 2 pipeline

• IMU-838

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Immunic AG portfolio CI brief
• Immunic AG pipeline updates RSS